[go: up one dir, main page]

WO1998016246A1 - Immunotherapie amelioree par cytokine pour tumeurs cerebrales - Google Patents

Immunotherapie amelioree par cytokine pour tumeurs cerebrales Download PDF

Info

Publication number
WO1998016246A1
WO1998016246A1 PCT/US1997/018455 US9718455W WO9816246A1 WO 1998016246 A1 WO1998016246 A1 WO 1998016246A1 US 9718455 W US9718455 W US 9718455W WO 9816246 A1 WO9816246 A1 WO 9816246A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine
cells
mmor
tumor
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/018455
Other languages
English (en)
Other versions
WO1998016246A9 (fr
Inventor
Henry Brem
Drew M. Pardoll
Reid C. Thompson
Elizabeth M. Jaffee
Kam W. Leong
Matthew G. Ewend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to JP10518504A priority Critical patent/JP2001502331A/ja
Priority to CA002267977A priority patent/CA2267977A1/fr
Priority to AU48182/97A priority patent/AU4818297A/en
Priority to EP97910921A priority patent/EP0930892A1/fr
Publication of WO1998016246A1 publication Critical patent/WO1998016246A1/fr
Publication of WO1998016246A9 publication Critical patent/WO1998016246A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • cytokines including IL-3 and IL-7 can be secreted from cells by applying the methods used for the cytokines described above or by the general procedures for genetically modifying nonimmunogenic murine fibrosarcoma described in Karp, S. E. , et al., /. Immunol. , 150:896-908 (1993) and Jaffee, E. et al., J. Immunotherapy, in press (1995).
  • the publications cited above describe methods of genetically engineering cells to secrete cytokines.
  • cancer vaccines expressing two or more cytokines from engineered vectors containing genes encoding two different cytokines or by sequential recombinant retrovirus-mediated genetic transductions can be prepared.
  • Example 4 Intracranial delivery of microencapsulated interleukin-2 produces long term memory and protects against re- challenges

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une thérapie permettant de traiter des patients atteints de cancer en combinant l'administration par voie générale d'une cytokine et d'un véhicule pharmaceutiquement acceptable avec l'administration locale d'une cytokine et d'un véhicule pharmaceutiquement acceptable. Dans le mode de réalisation préféré, les tumeurs cérébrales sont traitées au moyen d'une cytokine telle que le GM-CSF administré par voie générale, de préférence en combinaison avec un antigène tumoral tel que des cellules tumorales incapables de se répliquer, et d'une cytokine telle que l'IL-2 ou l'IL-4 administrée localement, de préférence dans un véhicule assurant sa libération lente tel que des cellules transduites, et de préférence des cellules tumorales incapables de se répliquer, ou incorporée dans des véhicules microparticulaires tels que des microsphères polymères.
PCT/US1997/018455 1996-10-16 1997-10-15 Immunotherapie amelioree par cytokine pour tumeurs cerebrales Ceased WO1998016246A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10518504A JP2001502331A (ja) 1996-10-16 1997-10-15 脳腫瘍に対するサイトカインで増強した免疫療法
CA002267977A CA2267977A1 (fr) 1996-10-16 1997-10-15 Immunotherapie amelioree par cytokine pour tumeurs cerebrales
AU48182/97A AU4818297A (en) 1996-10-16 1997-10-15 Cytokine enhanced immunotherapy for brain tumors
EP97910921A EP0930892A1 (fr) 1996-10-16 1997-10-15 Immunotherapie amelioree par cytokine pour tumeurs cerebrales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73159796A 1996-10-16 1996-10-16
US08/731,597 1996-10-16

Publications (2)

Publication Number Publication Date
WO1998016246A1 true WO1998016246A1 (fr) 1998-04-23
WO1998016246A9 WO1998016246A9 (fr) 1998-08-13

Family

ID=24940192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018455 Ceased WO1998016246A1 (fr) 1996-10-16 1997-10-15 Immunotherapie amelioree par cytokine pour tumeurs cerebrales

Country Status (5)

Country Link
EP (1) EP0930892A1 (fr)
JP (1) JP2001502331A (fr)
AU (1) AU4818297A (fr)
CA (1) CA2267977A1 (fr)
WO (1) WO1998016246A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193970B1 (en) * 1993-12-14 2001-02-27 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
WO2001047546A3 (fr) * 1999-12-28 2001-12-06 Univ Brown Res Found Methodes pour l'immunotherapie antitumorale utilisant des cytokines et produits correspondants
WO2003080111A3 (fr) * 2002-03-25 2003-11-13 Technologies Biolactis Inc Agents chimiotherapeutiqes utilises en tant qu'adjuvants vaccinaux contre le cancer et procedes therapeutiques correspondants
JP2004501981A (ja) * 2000-06-29 2004-01-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
EP1076564A4 (fr) * 1998-04-02 2005-02-23 Univ California Procedes servant a augmenter le developpement de cellules presentant des antigenes et les reactions immunes antitumorales chez un patient humain
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2006008582A1 (fr) * 2004-06-30 2006-01-26 Sygnis Bioscience Gmbh / Co. Kg Traitement de troubles neurologiques avec des facteurs de croissance hematopoietiques
US9814682B2 (en) 2002-06-17 2017-11-14 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
US9861689B2 (en) 2015-09-25 2018-01-09 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241315A1 (fr) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
WO2020123716A1 (fr) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Il12 liée à la membrane, compositions et procédés de régulation accordable
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
EP3983538A1 (fr) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Compositions de ca2 et procédés de régulation ajustable
EP3983537A1 (fr) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Compositions de ca2 et procédés de régulation accordable
WO2021040736A1 (fr) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Compositions à base de car cd19 tandem et méthodes d'immunothérapie
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BELLDEGRUN ET AL: "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, 1993, pages 207 - 216, XP002057839 *
DRANOFF ET AL: "VACCINATION WITH IRRADIATED TUMOR CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTI-TUMOR IMMUNITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, vol. 90, 1993, pages 3539 - 3543, XP002057840 *
GOLUMBEK ET AL: "CONTROLLED RELEASE, BIODEGRADABLE CYTOKINE DEPOTS: A NEW APPROACH IN CANCER VACCINE DESIGN", CANCER RESEARCH, vol. 53, 1993, pages 5841 - 5844, XP002057841 *
HOLLINGSWORTH ET AL: "THE EFFECT OF COMBINED EXPRESSSION OF INTERLEUKIN 2 AND INTERLEUKIN 4 ON THE TUMORIGENICITY AND TREATMENT OF B16F10 MELANOMA", BRITISH JOURNAL OF CANCER, vol. 74, July 1996 (1996-07-01), pages 6 - 15, XP002057838 *
PAPPO ET AL: "ADMINISTRATION OF SYSTEMIC OR LOCAL INTERLEUKIN-2 ENHANCES THE ANTI-TUMOR EFFECTS OF INTERLEUKIN-12 GENE THERAPY", JOURNAL OF SURGICAL RESEARCH, vol. 58, 1995, pages 218 - 226, XP002057836 *
PIPPIN ET AL: "LOCAL IL-4 DELIVERY ENHANCES IMMUNE REACTIVITY TO MURINE TUMORS: GENE THERAPY IN COMBINATION WITH IL2", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 35 - 42, XP002057835 *
THOMPSON ET AL: "SYSTEMIC AND LOCAL PARACRINE CYTOKINE THERAPIES USING TRANSDUCED TUMOR CELLS ARE SYNERGISTIC IN TREATING INTRACRANIAL TUMORS", JOURNAL OF IMMUNOTHERAPY, vol. 19, no. 6, November 1996 (1996-11-01), pages 405 - 413, XP002057842 *
VAGLIANI ET AL: "INTERLEUKIN 12 POTENTIATES THE CURATIVE EFFECT OF A VACCINE BASED ON INTERLEUKIN 2-TRANSDUCED TUMOR CELLS", CANCER RESEARCH, vol. 56, 1 February 1996 (1996-02-01), pages 467 - 470, XP002057837 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193970B1 (en) * 1993-12-14 2001-02-27 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US7264820B2 (en) 1996-07-25 2007-09-04 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US7364726B2 (en) 1996-07-25 2008-04-29 The Regents Of The University Of California Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine
EP1076564A4 (fr) * 1998-04-02 2005-02-23 Univ California Procedes servant a augmenter le developpement de cellules presentant des antigenes et les reactions immunes antitumorales chez un patient humain
WO2001047546A3 (fr) * 1999-12-28 2001-12-06 Univ Brown Res Found Methodes pour l'immunotherapie antitumorale utilisant des cytokines et produits correspondants
JP2004501981A (ja) * 2000-06-29 2004-01-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US8114404B2 (en) 2000-08-11 2012-02-14 Mmrglobal, Inc. Method and composition for altering a B cell mediated pathology
US8133486B2 (en) 2000-08-11 2012-03-13 Mmrglobal, Inc. Method and composition for altering a B cell mediated pathology
US8637638B2 (en) 2000-08-11 2014-01-28 Mmrglobal, Inc. Method and composition for altering a B cell mediated pathology
WO2003080111A3 (fr) * 2002-03-25 2003-11-13 Technologies Biolactis Inc Agents chimiotherapeutiqes utilises en tant qu'adjuvants vaccinaux contre le cancer et procedes therapeutiques correspondants
US9814682B2 (en) 2002-06-17 2017-11-14 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
WO2006008582A1 (fr) * 2004-06-30 2006-01-26 Sygnis Bioscience Gmbh / Co. Kg Traitement de troubles neurologiques avec des facteurs de croissance hematopoietiques
US9861689B2 (en) 2015-09-25 2018-01-09 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
US11013790B2 (en) 2015-09-25 2021-05-25 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator

Also Published As

Publication number Publication date
AU4818297A (en) 1998-05-11
EP0930892A1 (fr) 1999-07-28
JP2001502331A (ja) 2001-02-20
CA2267977A1 (fr) 1998-04-23

Similar Documents

Publication Publication Date Title
WO1998016246A1 (fr) Immunotherapie amelioree par cytokine pour tumeurs cerebrales
WO1998016246A9 (fr) Immunotherapie amelioree par cytokine pour tumeurs cerebrales
CA2194555C (fr) Implantation de cellules tumorales destinee au traitement du cancer
Egilmez et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity
US5861159A (en) Controlled release of pharmaceutically active substances for immunotherapy
US6156305A (en) Implanted tumor cells for the prevention and treatment of cancer
EP0774964B1 (fr) Apport local controle d'agents chimiotherapeutiques permettant de traiter des tumeurs solides
US4832686A (en) Method for administering interleukin-2
JP4913321B2 (ja) 徐放性医薬組成物
CN101304759A (zh) 使用模式识别的受体-配体:脂质复合物的疫苗
Gu et al. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device
US9814682B2 (en) Vaccination with immuno-isolated cells producing an immunomodulator
Wang et al. Construction of single-injection vaccine using new time-controlled release system
EP2421505A2 (fr) Hydrogels pour administration combinatoire de biomolécules modulant l'immunité
JP2024050581A (ja) 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用
Egilmez et al. Controlled-release particulate cytokine adjuvants for cancer therapy
US20040005302A1 (en) Encapsulated cells to elicit immune responses
US12397052B2 (en) Microcapsule-based vaccine
CN119185520A (zh) 一种仿生自噬小体的肿瘤纳米疫苗及其制备方法与应用
EP1143934A1 (fr) Immunisation genetique avec administration conjointe d'acide nucleique et de cytokines
Amsden Review of osmotic pressure driven release of proteins from monolithic devices
TW442294B (en) Device and process for manufacturing a device for implanting tumor cells for the prevention and treatment of cancer
Stokes Jr Immunomodulatory biomaterials for cancer immunotherapy
CN120678910A (zh) 一种注射型免疫佐剂水凝胶、水凝胶-药物体系及制备方法与应用
JP2001199879A (ja) 薬物放出製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

ENP Entry into the national phase

Ref document number: 2267977

Country of ref document: CA

Ref country code: CA

Ref document number: 2267977

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 518504

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997910921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09284547

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997910921

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1997910921

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997910921

Country of ref document: EP